Company intelligence / Profile preview

CytImmune Sciences

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

CYT-6091, the company's lead therapeutic, has completed Phase 1 clinical trials at the National Cancer Institute with promising results and is advancing to Phase 2 studies. The Phase 1 trial demonstrated that gold nanoparticles trafficked to tumors, not healthy tissue, improving the safety of systemically administered TNF formulated as CYT-6091[4][5].

Therapeutic areas: Oncology
Modalities: NanomedicineGold nanoparticlesTNF alpha delivery system
Industry: Biotech

Drug pipeline

2 assets

Aurimune

Phase 2

Indications: Pancreatic cancer, Melanoma, Soft tissue sarcoma, Ovarian cancer, Breast cancer, Non-small-cell lung cancer

1 more asset in the full pipeline.

Request access →

Partnerships

AstraZenecaNational Cancer Institute

Beyond the preview

Go deeper on CytImmune Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytImmune Sciences.

Explore the full profile